EVKEEZA — REGENERON PHARMACEUTICALS, approved 2025-09-25 (BLA761181).
238 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.